Should you buy Sarepta Therapeutics stock now?
No, the technical signal for Sarepta Therapeutics is currently SELL. Sarepta Therapeutics trades at $16.80 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.532 with falling momentum (signal: -0.494); RSI is at 44.1 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $22.17 points to 32.0% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Sarepta Therapeutics stock?
The average analyst price target for Sarepta Therapeutics is $22.17. The current price is $16.80, which gives an upside of 32.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $19.95 and $24.39.
Is Sarepta Therapeutics a dividend stock?
No, Sarepta Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Sarepta Therapeutics stock?
Sarepta Therapeutics is rated as a stock with extreme risk. the annual standard deviation is 80.8%, which classifies the stock as extreme risk.
Is Sarepta Therapeutics overvalued?
No, Sarepta Therapeutics is considered undervalued based on the analyst price target (32.0% upside). Sarepta Therapeutics has the following valuation ratios: a P/E ratio of 45.5 (highly valued), a P/S ratio of 0.8, a P/B ratio of 1.0. The analyst price target suggests that the stock is undervalued by 32.0%.
Is Sarepta Therapeutics overbought?
No, Sarepta Therapeutics is not overbought. RSI is at 44.1 (neutral zone). The technical indicators show: RSI is at 44.1 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.5% above the 20-day average (short-term uptrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Sarepta Therapeutics earnings report?
The date of the next earnings report for Sarepta Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is Sarepta Therapeutics shorted?
Yes, Sarepta Therapeutics is shorted with 32.4% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Sarepta Therapeutics stock?
No, insiders are not buying Sarepta Therapeutics shares – they are net sellers. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 1,484,264 $ sold. Active sellers include Stephen Mayo, Mayo Stephen, Wong Ryan Ho-Yan and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Sarepta Therapeutics a good stock?
Based on our total score, Sarepta Therapeutics is rated as a mediocre stock with a total score of 52 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 63/100, Quality: 71/100, Momentum: 23/100. In addition: analysts see 32.0% upside to the price target; technical signal: Strong Sell. Whether Sarepta Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Sarepta Therapeutics stock?
The outlook for Sarepta Therapeutics based on current data: the average analyst price target is $22.17 (+32.0%); the stock is in a downtrend (below SMA50 and SMA200); the P/E ratio is 45.5 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Sarepta Therapeutics stock moving?
Sarepta Therapeutics is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 32.4% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Sarepta Therapeutics go?
The average analyst price target for Sarepta Therapeutics is $22.17, which corresponds to a potential gain of 32.0% from the current price of $16.80. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Sarepta Therapeutics fall?
We lack enough history to give a specific floor for Sarepta Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Sarepta Therapeutics do?
Sarepta Therapeutics driver en biopharma-virksomhed, der opdager og udvikler gen- og RNA-terapier. De fokuserer primært på sjældne sygdomme. De tjener penge på at sælge behandlinger for Duchennes muskeldystrofi. Blandt deres produkter er EXONDYS 51, VYONDYS 53 og AMONDYS 45. D... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Sarepta Therapeutics as an investment.
Did Sarepta Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Sarepta Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Sarepta Therapeutics making money or losing money?
Yes, Sarepta Therapeutics is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 3.0% — which is modest. The operating margin (profit before interest and taxes) is 49.1%. At a P/E ratio of 45.5, you currently pay 45.5 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Sarepta Therapeutics go bankrupt?
The bankruptcy risk of Sarepta Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is 0.19 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 159% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Sarepta Therapeutics have a lot of debt?
Yes, Sarepta Therapeutics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 159%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Sarepta Therapeutics service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is 16.8x, and net debt equals 12.4 years of earnings (EBITDA).
